氮化钛氧化物涂层支架与依维莫司洗脱支架在急性冠脉综合征中的5年临床结局:TIDES-ACS随机临床试验
TIDES-ACS多中心随机开放标签试验纳入1491例ACS患者,随机接受TiNO涂层支架(989例)或第三代EES(502例)。5年时主要复合终点(心源性死亡、MI或TLR)两组无显著差异(11.2% vs 12%,HR 0.94,95%CI 0.69-1.28,P=0.69),但TiNO组心源性死亡、MI和支架血栓发生率较低。
要点
- 5年主要复合终点TiNO涂层支架与EES无显著差异(HR 0.94,P=0.69)。
- TiNO组心源性死亡(HR 0.30)、MI(HR 0.64)和支架血栓(HR 0.43)风险显著低于EES。
核心结论
- ACS患者接受TiNO涂层支架或EES后5年主要复合终点无显著差异。
- TiNO涂层支架组心源性死亡、MI和支架血栓发生率显著低于EES组。
研究设计与样本
- 多中心、随机、对照、开放标签试验,在5个欧洲国家的12个临床中心进行,2014年1月至2016年8月入组。
- 共纳入1491例ACS患者(STEMI、NSTEMI或不稳定型心绞痛),至少1处原发病变,随机接受TiNO涂层支架(989例,66.3%)或EES(502例,33.7%)。
- 平均(SD)年龄62.7(10.8)岁,女性363例(24.3%)。
主要发现
- 5年主要复合终点事件:TiNO组111例(11.2%),EES组60例(12%),HR 0.94(95%CI 0.69-1.28),P=0.69。
临床怎么用
- 对于ACS患者,TiNO涂层支架可作为EES的替代选择,5年主要复合终点相当,且心源性死亡、MI和支架血栓风险更低。
- 需结合个体出血缺血风险、病变特征和支架可用性综合决策。
局限性
- 开放标签设计可能引入偏倚。
- 随机分组比例不均衡(TiNO组66.3% vs EES组33.7%)。
- 原文未报告其他局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
IMPORTANCE: Titanium-nitride-oxide (TiNO)-coated stents show faster strut coverage compared with drug-eluting stents without excessive intimal-hyperplasia observed in bare metal stents. It is important to study long-term clinical outcomes after treatment of patients with an acute coronary syndrome (ACS) by TiNO-coated stents, which are neither drug-eluting stents nor bare metal stents. OBJECTIVE: To compare the rate of main composite outcome of cardiac death, myocardial infarction (MI), or ischemia-driven target lesion revascularization at 5 years in patients with ACS randomized to receive either a TiNO-coated stent or a third-generation everolimus-eluting stent (EES). DESIGN, SETTING, AND PARTICIPANTS: This multicenter, randomized, controlled, open-label trial was conducted in 12 clinical sites in 5 European countries and enrolled patients from January 2014 to August 2016. Patients presenting with ACS (ST-segment elevation MI, non-ST-segment elevation MI, and unstable angina) with at least 1 de novo lesion were randomized to receive either a TiNO-coated stent or an EES. The present report analyzes the long-term follow-up for the main composite outcome and its individual components. Analysis took place between November 2022 to March 2023. MAIN OUTCOME: The primary end point was a composite of cardiac death, MI, or target lesion revascularization at 12-month follow-up. RESULTS: A total of 1491 patients with ACS were randomly assigned to receive either TiNO-coated stents (989 [66.3%]) or EES (502 [33.7%]). The mean (SD) age was 62.7 (10.8) years, and 363 (24.3%) were female. At 5 years, the main composite outcome events occurred in 111 patients (11.2%) in the TiNO group vs 60 patients (12%) in the EES group (hazard ratio [HR], 0.94; 95% CI, 0.69-1.28; P = .69). The rate of cardiac death was 0.9% (9 of 989) vs 3.0% (15 of 502) (HR, 0.30; 95% CI, 0.13-0.69; P = .005), the rate of MI was 4.6% (45 of 989) vs 7.0% (35 of 502) (HR, 0.64; 95% CI, 0.41-0.99; P = .049), the rate of stent thrombosis was 1.2% (12 of 989) vs 2.8% (14 of 502) (HR, 0.43; 95% CI, 0.20-0.93; P = .034), and the rate of target lesion revascularization was 7.4% (73 of 989) vs 6.4% (32 of 502) (HR, 1.16; 95% CI, 0.77-1.76; P = .47) in the TiNO-coated stent arm and in the EES arm, respectively. CONCLUSION AND RELEVANCE: In this study, patients with ACS had a main composite outcome that was not different 5 years after TiNO-coated stent or EES. TRIAL REGISTRATION: ClinicalTrials.gov Identifier: NCT02049229.
引用
- Bouisset, Sia, Mizukami, et al. Titanium-Nitride-Oxide-Coated vs Everolimus-Eluting Stents in Acute Coronary Syndrome: 5-Year Clinical Outcomes of the TIDES-ACS Randomized Clinical Trial. JAMA Cardiol. 2023. PMID: 37203243. doi:10.1001/jamacardio.2023.1373
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。